https://scholars.lib.ntu.edu.tw/handle/123456789/568558
標題: | Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma | 作者: | Omata M. Lesmana L.A. Tateishi R. PEI-JER CHEN Lin S.-M. Yoshida H. Kudo M. Lee J.M. Choi B.I. Poon R.T.P. Shiina S. ANN-LII CHENG Jia J.-D. Obi S. Han K.H. Jafri W. Chow P. Lim S.G. Chawla Y.K. Budihusodo U. Gani R.A. Lesmana C.R. Putranto T.A. Liaw Y.F. Sarin S.K. |
公開日期: | 2010 | 出版社: | Springer New York | 卷: | 4 | 期: | 2 | 起(迄)頁: | 439-474 | 來源出版物: | Hepatology International | 摘要: | Introduction: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations. Methods: The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements. Results: Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference. ? 2010 Asian Pacific Association for the Study of the Liver. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984586846&doi=10.1007%2fs12072-010-9165-7&partnerID=40&md5=143fe9bd3d703d4c1d2d99e345e2f621 https://scholars.lib.ntu.edu.tw/handle/123456789/568558 |
ISSN: | 1936-0533 | DOI: | 10.1007/s12072-010-9165-7 | SDG/關鍵字: | aflatoxin; alpha fetoprotein; bevacizumab; capecitabine; cetuximab; cisplatin; decarboxyprothrombin; doxorubicin; epidermal growth factor receptor antibody; epirubicin; erlotinib; farnoquinone; fluorouracil; gefitinib; gemcitabine; glitazone derivative; glypican 3; hepatitis B vaccine; interferon; lamivudine; metformin; mitomycin C; mitoxantrone; oxaliplatin; placebo; sorafenib; sunitinib; thalidomide; tumor marker; unindexed drug; advanced cancer; alcohol consumption; antineoplastic activity; ascites; bleeding; bone marrow suppression; cancer screening; cardiotoxicity; chemoembolization; clinical trial; coffee; computer assisted tomography; constipation; desquamation; diagnostic test; diarrhea; dizziness; drug efficacy; drug eruption; drug safety; drug tolerability; echography; edema; evidence based medicine; family history; fatigue; geographic distribution; hand foot syndrome; hemochromatosis; hepatic encephalopathy; hepatitis B; hepatitis C; human; Human immunodeficiency virus infection; hypertension; infection; insulin resistance; liver carcinoma; liver cell carcinoma; liver cirrhosis; liver resection; liver transplantation; loading drug dose; lymphocytopenia; medical specialist; mixed infection; neutropenia; nonalcoholic fatty liver; nuclear magnetic resonance imaging; positron emission tomography; primary prevention; priority journal; radiofrequency ablation; review; secondary prevention; sensitivity and specificity; sex difference; side effect; smoking; somnolence; thrombocytopenia; thrombosis; vaccination; virus transmission |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。